Literature DB >> 7963564

Limited expression of C/EBP family proteins during B lymphocyte development. Negative regulator Ig/EBP predominates early and activator NF-IL-6 is induced later.

C L Cooper1, A L Berrier, C Roman, K L Calame.   

Abstract

The importance of C/EBP proteins in B cell biology is suggested by the occurrence of functionally important C/EBP binding sites in Ig gene enhancers and promoters, and the knowledge that family member NF-IL-6 is induced in other systems in response to regulators of B cell differentiation. We have studied the expression pattern and activity of C/EBP family transcriptional regulators in B cells at different developmental stages by using B cell lines and normal splenic B cells. Two family members, Ig/EBP and NF-IL-6, seem to be the major regulators of C/EBP site-dependent transcriptional activity in B cells. Negative regulator Ig/EBP is predominantly present in early B cells; activator NF-IL-6 increases in more mature B cells and is induced by LPS activation of splenic B cells. LIP, an N-terminally truncated form of NF-IL-6, was found in most B cell lines tested; LIP can act as a weak transcriptional activator in B cell lines. Partly as a result of the differential amounts of C/EBP family proteins, C/EBP sites do not function as activator sites in early B cells but are activator sites in terminally differentiated B cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963564

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  The interferon signaling network and transcription factor C/EBP-beta.

Authors:  Hui Li; Padmaja Gade; Weihua Xiao; Dhan V Kalvakolanu
Journal:  Cell Mol Immunol       Date:  2007-12       Impact factor: 11.530

2.  CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4(+) T cells.

Authors:  A J Henderson; K L Calame
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

3.  C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes.

Authors:  A J Henderson; X Zou; K L Calame
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

4.  C/EBPbeta is a negative regulator of human papillomavirus type 11 in keratinocytes.

Authors:  H Wang; K Liu; F Yuan; L Berdichevsky; L B Taichman; K Auborn
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Erythroid overexpression of C/EBPgamma in transgenic mice affects gamma-globin expression and fetal liver erythropoiesis.

Authors:  G Zafarana; R Rottier; F Grosveld; S Philipsen
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

6.  Regulation of the pro-B-cell-specific enhancer of the Id1 gene involves the C/EBP family of proteins.

Authors:  S Saisanit; X H Sun
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

7.  Ig/EBP (C/EBP gamma) is a transdominant negative inhibitor of C/EBP family transcriptional activators.

Authors:  C Cooper; A Henderson; S Artandi; N Avitahl; K Calame
Journal:  Nucleic Acids Res       Date:  1995-11-11       Impact factor: 16.971

8.  C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.

Authors:  Rekha Pal; Martin Janz; Deborah L Galson; Margarete Gries; Shirong Li; Korinna Jöhrens; Ioannis Anagnostopoulos; Bernd Dörken; Markus Y Mapara; Lisa Borghesi; Lela Kardava; G David Roodman; Christine Milcarek; Suzanne Lentzsch
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113

9.  v-Abl activates c-myc transcription through the E2F site.

Authors:  K K Wong; X Zou; K T Merrell; A J Patel; K B Marcu; S Chellappan; K Calame
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

10.  Multiple transcription factor binding sites predict AID targeting in non-Ig genes.

Authors:  Jamie L Duke; Man Liu; Gur Yaari; Ashraf M Khalil; Mary M Tomayko; Mark J Shlomchik; David G Schatz; Steven H Kleinstein
Journal:  J Immunol       Date:  2013-03-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.